Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Freeman, James B ^a   Gray, Elin S ^a   Millward, Michael ^b   Pearce, Robert ^a   Ziman, Melanie ^a,b  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Circulating tumour cells; Immunomagnetic enrichment; Melanoma; Multi marker

Indexed keywords

CD146 ANTIGEN; PROTEIN ABCB5; PROTEIN CD271; PROTEIN MCSP; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CELL COUNT; CANCER PATIENT; CANCER STAGING; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; ENRICHMENT CULTURE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOMAGNETIC SEPARATION; MELANOMA CELL; METASTATIC MELANOMA; PROTEIN EXPRESSION; PROTEIN TARGETING;

FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOMAGNETIC SEPARATION; MELANOMA; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84866169878     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-192     Document Type: Article

References (49)

1. Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, Samlowski WE, Leachman SA, Dirk Noyes R, Wittwer CT, Perreard L, Bernard PS. Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 2005, 104:1678-1686. 10.1002/cncr.21372, 16116595.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206. 10.1200/JCO.2009.23.4799, 2793035, 19917835.
3. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR, Wang HJ, Hseuh E, O'Day SJ, Hoon DS. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005, 51:981-988. 10.1373/clinchem.2004.045096, 2856477, 15817820.
4. Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A. Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med 2007, 11:1052-1068. 10.1111/j.1582-4934.2007.00091.x, 17979882.
5. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Davidson BS, Sussman JJ, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006, 24:2849-2857. 10.1200/JCO.2005.03.2342, 16782924.
6. Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, Gogas H, Stratigos AJ, Katsambas AD, Koutsilieris M. Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev 2011, 37:284-290. 10.1016/j.ctrv.2010.10.002, 21106295.
7. Steen S, Nemunaitis J, Fisher T, Kuhn J. Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proc (Bayl Univ Med Cent) 2008, 21:127-132.
8. Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmuller G, Fierlbeck G, Klein CA. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 2004, 10:531-537. 10.1158/1078-0432.CCR-0424-03, 14760074.
9. Austrup F, Uciechowski P, Eder C, Bockmann B, Suchy B, Driesel G, Jackel S, Kusiak I, Grill HJ, Giesing M. Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br J Cancer 2000, 83:1664-1673. 10.1054/bjoc.2000.1501, 2363462, 11104564.
10. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-3221. 10.1200/JCO.2007.15.8923, 18591556.
11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791. 10.1056/NEJMoa040766, 15317891.
12. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309. 10.1158/1078-0432.CCR-08-0872, 18829513.
13. Lobodasch K, Frohlich F, Rengsberger M, Schubert R, Dengler R, Pachmann U, Pachmann K. Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse. Breast 2007, 16:211-218. 10.1016/j.breast.2006.12.005, 17291754.
14. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009, 20:27-33.
15. Pachmann K, Camara O, Kavallaris A, Schneider U, Schunemann S, Hoffken K. Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res 2005, 7:R975-R979. 10.1186/bcr1328, 1410761, 16280045.
16. Pachmann K, Dengler R, Lobodasch K, Frohlich F, Kroll T, Rengsberger M, Schubert R, Pachmann U. An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer. J Cancer Res Clin Oncol 2008, 134:59-65.
17. Raynor MP, Stephenson SA, Pittman KB, Walsh DC, Henderson MA, Dobrovic A. Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. J Hematol Oncol 2009, 2:24. 10.1186/1756-8722-2-24, 2712470, 19500345.
18. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009, 115:581-590. 10.1007/s10549-008-0143-x, 18679793.
19. Arenberger P, Arenbergerova M, Vohradnikova O, Kremen J. Early detection of melanoma progression by quantitative real-time RT-PCR analysis for multiple melanoma markers. Keio J Med 2008, 57:57-64. 10.2302/kjm.57.57, 18382126.
20. Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, Morton DL. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000, 60:2253-2257.
21. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, Kuo C, Foshag LJ, Nizze AJ, Morton DL. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995, 13:2109-2116.
22. Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, Bystryn JC. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003, 9:1497-1502.
23. Benez A, Geiselhart A, Handgretinger R, Schiebel U, Fierlbeck G. Detection of circulating melanoma cells by immunomagnetic cell sorting. J Clin Lab Anal 1999, 13:229-233. 10.1002/(SICI)1098-2825(1999)13:5<229::AID-JCLA7>3.0.CO;2-Y, 10494132.
24. Faye RS, Aamdal S, Hoifodt HK, Jacobsen E, Holstad L, Skovlund E, Fodstad O. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res 2004, 10:4134-4139. 10.1158/1078-0432.CCR-03-0408, 15217950.
25. Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M, O'Day SJ, Morton DL, Ferrone S, Hoon DS. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem 2009, 55:757-764. 10.1373/clinchem.2008.116467, 2760934, 19233913.
26. Liu Z, Fusi A, Klopocki E, Schmittel A, Tinhofer I, Nonnenmacher A, Keilholz U. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med 2011, 9:70. 10.1186/1479-5876-9-70, 3119001, 21595914.
27. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H, Okuyama R. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 2012, 106:939-946. 10.1038/bjc.2012.12, 22281663.
28. Fusi A, Liu Z, Kummerlen V, Nonnemacher A, Jeske J, Keilholz U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med 2012, 10:52. 10.1186/1479-5876-10-52, 3337808, 22433180.
29. Mangahas CR, dela Cruz GV, Schneider RJ, Jamal S. Endothelin-1 upregulates MCAM in melanocytes. J Invest Dermatol 2004, 123:1135-1139. 10.1111/j.0022-202X.2004.23480.x, 15610525.
30. Medic S, Ziman M. PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas). PLoS One 2010, 5:e9977. 10.1371/journal.pone.0009977, 2858648, 20421967.
31. Shih IM, Elder DE, Hsu MY, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 1994, 145:837-845. 1887332, 7943174.
32. Chen KG, Szakacs G, Annereau JP, Rouzaud F, Liang XJ, Valencia JC, Nagineni CN, Hooks JJ, Hearing VJ, Gottesman MM. Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res 2005, 18:102-112. 10.1111/j.1600-0749.2005.00214.x, 15760339.
33. Ma J, Lin JY, Alloo A, Wilson BJ, Schatton T, Zhan Q, Murphy GF, Waaga-Gasser AM, Gasser M, Stephen Hodi F, et al. Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 2010, 402:711-717. 10.1016/j.bbrc.2010.10.091, 2998991, 20977885.
34. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349. 10.1038/nature06489, 18202660.
35. Sekulic A, Haluska P, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008, 83:825-846. 10.4065/83.7.825, 2739389, 18613999.
36. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137. 10.1038/nature09161, 2898751, 20596026.
37. Lorenz HM, Lagoo AS, Hardy KJ. The cell and molecular basis of leukocyte common antigen (CD45)-triggered, lymphocyte function-associated antigen-1-/intercellular adhesion molecule-1-dependent, leukocyte adhesion. Blood 1994, 83:1862-1870.
38. Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Bromberg-White JL, Duesbery NS, Frankel AE. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Mol Cancer Ther 2008, 7:1218-1226. 10.1158/1535-7163.MCT-08-0024, 2757055, 18483309.
39. Piyamongkol W, Bermudez MG, Harper JC, Wells D. Detailed investigation of factors influencing amplification efficiency and allele drop-out in single cell PCR: implications for preimplantation genetic diagnosis. Mol Hum Reprod 2003, 9:411-420. 10.1093/molehr/gag051, 12802048.
40. Harbst K, Staaf J, Masback A, Olsson H, Ingvar C, Vallon-Christersson J, Ringner M, Borg A, Jonsson G. Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. Melanoma Res 2010, 20:381-391.
41. Taback B, Morton DL, O'Day SJ, Nguyen DH, Nakayama T, Hoon DS. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res 2001, 158:78-92. 10.1007/978-3-642-59537-0_8, 11092035.
42. Ireland A, Millward M, Pearce R, Lee M, Ziman M. Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis 2011, 28:327-336. 10.1007/s10585-010-9368-2, 21311956.
43. Bockhorn M, Jain RK, Munn LL. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?. Lancet Oncol 2007, 8:444-448. 10.1016/S1470-2045(07)70140-7, 2712886, 17466902.
44. Cavallaro U, Christofori G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta 2001, 1552:39-45.
45. Rocken M. Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 2010, 120:1800-1803. 10.1172/JCI43424, 2877965, 20501952.
46. Ulmer A, Beutel J, Susskind D, Hilgers RD, Ziemssen F, Luke M, Rocken M, Rohrbach M, Fierlbeck G, Bartz-Schmidt KU, Grisanti S. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 2008, 14:4469-4474. 10.1158/1078-0432.CCR-08-0012, 18628461.
47. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012, 13:688-695. 10.1016/S1470-2045(12)70209-7, 22677156.
48. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377. 10.1056/NEJMoa0800668, 18596266.
49. Yang MJ, Chiu HH, Wang HM, Yen LC, Tsao DA, Hsiao CP, Chen YF, Wang JY, Lin SR. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol 2010, 17:624-633. 10.1245/s10434-009-0831-8, 19937133.